Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute traumatic spinal cord injury

Trial Profile

Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute traumatic spinal cord injury

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs FAB 117-HC (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; First in man
  • Acronyms SPINE
  • Sponsors Ferrer
  • Most Recent Events

    • 23 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 26 Sep 2016 Status changed from planning to not yet recruiting.
    • 18 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top